Clinical trial · Observational

ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

Observational Clinical Study of Autologous Hematopoietic Stem Cell Transplantation and Chemotherapy as First-Line Consolidation Therapy After Obtaining a Complete Therapeutic Response in T-Cell Lymphoma

NCT06149390CI-TRIAL-00071786completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

To compare the effectiveness of autologous hematopoietic stem cell transplantation and chemotherapy as first-line consolidation therapy after obtaining a complete therapeutic response in T-cell lymphoma through a multicenter retrospective real-world study in China.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
T-cell Lymphoma Adults	T-Cell Non-Hodgkin Lymphoma	ALIAS	0.85

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
consolidation with ASCT	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

label
Consoliation with ASCT
description
consolidation therapy with first-line ASCT in PTCL patients who achieved CR after first-line treatment.
interventionNames
1. Drug: consolidation with ASCT
label
non-ASCT
description
consolidation therapy without first-line ASCT in PTCL patients who achieved CR after first-line treatment.

Primary outcomes (1)

measure
overall survival
timeFrame
through study completion, an average of 2 year
description
death as a result of any cause

Secondary outcomes (3)

measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 75 Years

Show eligibility criteria text

Inclusion Criteria:

* Pathological diagnosis of T-cell lymphoma, including, but not limited to, Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell lymphoma (AITL) , ALK-negative anaplastic large cell lymphoma (ALCL, ALK-negative), Enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTCL), and extranodal NK/T-cell lymphoma (ENKTL )
* 18-75 years old;
* Achievement of a complete response (CR) post-chemotherapy;
* Obtaining a complete response (CR) after chemotherapy;-Consistent follow-up visits post-treatment, with comprehensive follow-up data available;

Exclusion Criteria:

* Initially diagnosed with ALK-positive Anaplastic Large Cell Lymphoma (ALCL, ALK- - -CR was not achieved after treatment;
* Lack of complete follow-up information or lack of consent for follow-up and data collection
* T-cell lymphoma secondary to other malignancies

References

Publications (0)

Data not yet available

No reference posted for this study.